To further investigate the effects of the combination of an EZH2 inhibitor and gefitinib on primary gefitinib-resistant cells, we treated the EGFR-WT NSCLC cell lines A549 and H1299 with the EZH2 inhibitors DZNep and GSK343. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.